To study effect of the early application of Evolocumab on blood lipid profile and cardiovascular prognosis in patients with extremely high-risk acute coronary syndrome
Latest Information Update: 22 Aug 2022
Price :
$35 *
At a glance
- Drugs Evolocumab (Primary) ; Atorvastatin; Ezetimibe
- Indications Acute coronary syndromes
- Focus Adverse reactions
- 22 Aug 2022 New trial record
- 30 Jul 2022 Results published in the International Heart Journal